Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)

Sponsor
University Of Nigeria Teaching Hospital
Study ID
NCT07297290
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Insulin Resistance
  • Obesity (Body Mass Index >30 kg/m2)
  • Obesity and Cardiovascular Risk

Eligibility Criteria

Sex
ALL
Age
20 Years - 59 Years
Healthy Volunteers
Not accepted

Interventions

  • Metformin — DRUG
    Metformin 500mg extended release tablets taken to a maximum of 1500mg once daily
  • Placebo — DRUG
    Starch-based, identical looking placebo

Study Details

Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers. Currently approved anti-obesity drugs and surgery are expensive and not readily available in Nigeria. Metformin, approved for type 2 diabetes, has been shown to promote weight loss among obese patients in high income countries. However, metformin's effects have not yet been demonstrated in Black African populations, which may have different genetic and environmental predispositions to obesity and to the effect of metformin. This blinded, placebo-controlled, randomized trial is determining the effect of metformin on weight loss, cardiovascular disease risk and insulin resistance in Black Nigerians.

Key Dates

First listed
Dec 22, 2025
Start date
Jul 23, 2025
Status verified
Dec 2025
Primary completion
Mar 31, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
220 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment arm
    Metformin 500mg extended release tablets taken once daily to a maximum dose of 1500mg daily
  • Placebo Comparator: Control arm
    Identical-looking placebo

Primary Outcome Measure

Effect of Metformin on body weight change [ Time Frame: 24 months ]

Central Contacts

Related Studies